Steffen Mueller

Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ.

Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA.

Synedgen, Inc. operates as a biotechnology company leveraging a proprietary glycomics technology platform to develop modified therapeutic polysaccharides that target mucosal surfaces in genetic and acquired disorders. The firm’s products include Prisyna oral care and Synedgen wound care. The company was founded by William P. Wiesmann and Shenda Baker in 2009 and is headquartered in Claremont, CA.

Cardea Bio, Inc. develops bioelectronics for use in research and diagnostics. Its products include AGILE 100 and pipeline. The company was founded by Ross Bundy, Kiana Aran, and Brett Goldsmith in 2013 and is headquartered in San Diego, CA.

CONNECT creates and scales companies in the technology and life sciences sectors. It creates an environment in which entrepreneurs and C-suite executives have access to the people, capital, and technology resources. The organization was founded in 1985 and is headquartered in San Diego, CA.

Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA.

Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria.

InDevR, Inc. develops and delivers analytical tools for detection and characterization of biological molecules and microorganisms. The firm offers on the ampliPHOX Colorimetric Detection platform and Custom Arrays to enable its customers a low risk means to explore the high utility of focused microarrays. The company was founded by Kathy L. Rowlen, Laura Kuck and John W. Birks in 2003 and is headquartered in Boulder, CO.

Global Health Investment Fund seeks investment opportunities in global health technologies. The fund invests in new drugs & vaccines, emerging diagnostic tools, child-friendly formulations of existing products, expanding manufacturing capacity and other applications. It provides financing in the form of mezzanine for later-stage capital requirements.

LHGP Asset Management LLP (Private Equity) (LHGP Asset Management) is a private equity arm of Lion's Head Global Partners LLP founded in 2018. The firm is headquartered in Westminster, United Kingdom.

Univercells SA designs single-use cost-efficient bioprocess solutions to open the next chapter in bio manufacturing. The company was founded by Jose Castillo, Guillaume De Viron and Hugues Bultot in 2013 and is headquartered in Gosselies, Belgium.

X-Vax Technology, Inc. operates as a biotechnology company. The company was founded in 2015 and is headquartered in New York, NY.

DepYmed , Inc. is a cancer and rare disease therapeutic development company. The company is headquartered in Farmingdale, NY.

IanTech, Inc. develops ophthalmic devices for cataract surgery. Its products include miLoop, miPhaco, miMissions, and miResources. The company was founded by Luke Clauson and Sean Ianchulev and is headquartered in Reno, NV.

DTx Pharma, Inc. engages in the provision of biotechnology solutions. It focuses on the utilization of fatty acids to enable the delivery of RNA therapeutics to tissues and organ systems beyond the liver. The company was founded by Arthur T. Suckow, John Grundy, and Adam Pavlicek in August 2017 and is headquartered in San Diego, CA.

Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York.

VitriVax, Inc. is a biotechnology company based in Boulder, CO that partners with vaccine developers to create thermostable vaccines that can be delivered in a single shot. The company's proprietary atomic layering thermostable antigen and adjuvant (alta™) technology platform enables vaccines to be shipped ly without refrigeration or freezing, last for years on the shelf, and only require one patient interaction to deliver multiple doses. The alta™ technology can be applied to a wide variety of vaccine antigens and adjuvants to protect against thermal and chemical degradation and enable controlled release, incorporating prime doses and additional booster doses in a single-shot administration. The company was founded by Robert Garcea and Theodore Randolph, and the CEO is Matthew Raider.

Inprother ApS is a biotechnology company based in Copenhagen, Denmark. The Danish company aims to develop novel immunotherapies that target the human endogenous retroviruses (HERVs) as tumor-specific antigens. The company is funded by the Novo Nordisk Bioinnovation Institute and by grants from the Danish Innovation Fund and Eurostars. Inprother has put in place a world-class scientific team and created an emerging product development pipeline, including a leading program targeted to enter clinics in 2024. Inprother's approach is based on the research of founder and CTO, Dr. Peter Holst, and CTO, Dr. Anne-Marie Andersson. The company was founded in 2011 by Peter Johannes Holst. Jordi Naval has been the CEO of the company since 2021.

Curevo, Inc. is a clinical stage company based in South Korea that aims to bring next generation vaccines to the market quickly and efficiently. The company is based in Seattle, WA. The company's partners include Mogam Institute for Biomedical Research and GC Pharma. Curevo is currently in phase 2 of a shingles study to evaluate the safety, tolerability, and immunogenicity of their vaccine. The company's goal is to reduce the burden of infectious disease with a focus on safe and highly effective shingles and varicella vaccines. Curevo was founded in 2018, and the CEO is George Simeone.